Difference between revisions of "Fluvoxamine-amitriptyline"
From Psychiatrienet
| Line 3: | Line 3: | ||
| to = amitriptyline | | to = amitriptyline | ||
| stop = | | stop = | ||
| + | {{stopFluvoxamine}} | ||
| + | |||
| + | |||
* '''Before day 1:''' gradually reduce dosage of fluvoxamine to a maximum of 100 mg/day when the dosage is > 100 mg/day. | * '''Before day 1:''' gradually reduce dosage of fluvoxamine to a maximum of 100 mg/day when the dosage is > 100 mg/day. | ||
* '''Day 1:''' reduce dosage of fluvoxamine to a maximum of 50 mg/day. | * '''Day 1:''' reduce dosage of fluvoxamine to a maximum of 50 mg/day. | ||
Revision as of 13:57, 28 October 2015
| ||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||
Switch medication from fluvoxamine to amitriptyline.[1] [2]
Stop fluvoxamine - Before day 1: gradually reduce dosage of fluvoxamine to a maximum of 50 mg/day, when this dosage is > 50 mg/day.
- Day 1: reduce dosage of fluvoxamine further to 25 mg/day.
- Day 8: stop administration of fluvoxamine.
- Before day 1: gradually reduce dosage of fluvoxamine to a maximum of 100 mg/day when the dosage is > 100 mg/day.
- Day 1: reduce dosage of fluvoxamine to a maximum of 50 mg/day.
- Day 8: stop administration of fluvoxamine
Start amitriptyline- Day 1: simultaneously start administration of amitriptyline in a low dosage of 25 mg/day.
- Day 8: continue administration of amitriptyline in a dosage of 50 mg/day.
- Start low, go slow!
More information- Fluvoxamine is an inhibitor of CYP1A2, CYP2C19 and CYP3A4 (moderate), which metabolize amitriptyline.
- Occurrence of the serotonin syndrome is not likely, but theoretically possible, so caution is necessary.
- This switch is currently being reviewed.
- ↑ Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
- ↑ Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.
